Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Apple

AbbVie

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Apollo Investment

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Preferred Apartment Communities

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Brookfield Infrastructure Partners L.P.

Bayerische Motoren Werke AG

My Dividend Portfolio: July 2021 Update - 99 Holdings, 35 Buys, Dividend Record

Bayer on Thursday lifted its outlook for 2021, citing double digit growth rates at all divisions during the second-quarter, most notably its pharmaceuticals unit.

Bayer raises outlook after strong Q2

Bayer on Thursday said it acquired U.S.-based biopharmaceuticals company Vividion Therapeutics for up to $2 billion to boost its ability to discover new treatments and lift the value of its drug pipeline.

Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion

Bayer to acquire Vividion Therapeutics in a $2 billion deal

Germany's Bayer said on Thursday that it would post an additional provision of $4.5 billion related to litigation of its Roundup weedkiller.

Bayer posts additional $4.5 billion provision for Roundup litigation

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer today provided an update on its five-point plan to address future Roundup™ litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to closure of this litigation. The first scenario is based on obtaining a favorable decision by the United States Supreme Court on

Bayer Provides Update on Path to Closure of Roundup™ Litigation

German chemicals maker Bayer said on Wednesday it may appeal an order in a U.S. legal case to pay $185 million to four staff members of a school in the state of Washington over exposure to polychlorinated biphenyls, or PCBs, made by the former Monsanto Co.

Bayer says to appeal U.S. court ruling on PCBs if necessary

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Denise Vitola is joining the Bayer Communications Team as Vice President of Brand Integration, PR, Social and Influencer for Consumer Health. In this role, Vitola will be responsible for leading strategy for integrated brand PR, social media and influencer marketing for all Consumer Health U.S. brands. For the last two years, Vitola has played an integral role as a consultant leading internal communications and brand PR for Bayer Consumer H

Denise Vitola Joins Bayer Communications Team

Bayer Aktiengesellschaft (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bayer Aktiengesellschaft (BAYRY) Upgraded to Buy: Here's What You Should Know

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

The FDA on Friday approved Bayer AG's (OTC: BAYRY) chronic kidney disease (CKD) drug Kerendia (finerenone), the first and only nonsteroidal mineralocorticoid receptor antagonist. Finerenone is indicated to reduce the risk of kidney function decline, kidney failure, cardiovascular death, nonfatal heart attacks, and hospitalization for heart failure in patients with chronic kidney disease associated with Type 2 diabetes.

Bayer's Kerendia Scores Long-Awaited Kidney & Heart Disease Nod For Type 2 Diabetes

Pfizer

Regeneron Pharmaceuticals

Now's the time to get into these companies while their valuation is still favorable.

3 Top Biotech Stocks to Buy in July

AstraZeneca

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season

Eli Lilly

Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.

3 Big Drugmakers Likely to be in Focus in Second Half of 2021

Johnson & Johnson

J&J (JNJ) and its partner Bayer seek approval of Xarelto as a treatment and prevention for venous thromboembolism in pediatric patients.

J&J (JNJ)/Bayer Seek Nod for Xarelto for Blood Clots in Kids

Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of the investigational combination of the cancer treatments Aliqopa® (copanlisib) and rituximab. The U.S. submission is for the treatment of patients with relapsed indolent B-cell non-Hodgkin's Lymphoma (iNHL) and is outside of the

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

WHIPPANY, N.J.--(BUSINESS WIRE)--As part of a continued commitment to the worldwide cancer community, Bayer announced today the first global ‘Precision Oncology Patient Innovation Awards.' The 2021 Awards aim to foster innovation and collaboration to improve access to precision oncology care and tackle inequalities for people with cancer around the world. The Awards are focused on supporting people with cancer types that are known to harbor rare genomic alterations that may benefit from genomic

Bayer Announces First ‘Precision Oncology Patient Innovation Awards'

Bayer AG's (OTC: BAYRY) Parkinson's disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer's subsidiary BlueRock Therapeutics's trial will eventually enroll 10 participants.

Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials

BERLIN--(BUSINESS WIRE)--Bayer AG announced today that BlueRock Therapeutics (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, successfully administered the first dose of its investigational pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson's disease patient in their open-label Phase 1 clinical safety and tolerability study. In parallel a gene therapy investigational program also targeted at providing advanced therapies f

Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson's Disease

Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline. Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from the Weill Cornell Medical College in NYC.

Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. Through this acquisition, Bayer will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA). The acquisition broadens Bayer's existing oncology portfolio of targeted alpha therapies (TATs), which curre

Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer

A U.S. judge rejected Bayer AG's (OTC: BAYRY) plan to try and limit the cost of future class action claims that its Roundup weedkiller causes cancer, saying that parts of the plan were “clearly unreasonable,” reports Reuters. The company called into question the future sale of glyphosate-based products to gardeners in the U.S. and said it would review plans to settle around 30,000 legal claims.

Bayer Mulls Ending US Retail Sales Of Weedkiller Glyphosate: Reuters

Bayer set out a five-point plan to address potential future claims that its Roundup weedkiller had caused cancer.

U.S. Judge Rejects Bayer's $2 Billion Deal to Settle Future Roundup Cancer Claims

News for Bayer AG Stock (BAYRY)